108 related articles for article (PubMed ID: 30981)
1. Potentiation of apomorphine action in rats by l-prolyl-l-leucyl-glycine amide.
Kostrzewa RM; Kastin AJ; Sobrian SK
Pharmacol Biochem Behav; 1978 Sep; 9(3):375-8. PubMed ID: 30981
[TBL] [Abstract][Full Text] [Related]
2. Effects of L-prolyl-L-leucyl-glycine amide (MIF-I) on dopaminergic neurons.
Kostrzewa RM; Spirtes MA; Klara JW; Christensen CW; Kastin AJ; Joh TH
Pharmacol Biochem Behav; 1976; 5(Suppl 1):125-7. PubMed ID: 13412
[TBL] [Abstract][Full Text] [Related]
3. The effects of prolyl-leucyl-glycine amide on drug-induced rotation in lesioned rats.
Smith JR; Morgan M
Gen Pharmacol; 1982; 13(3):203-7. PubMed ID: 6124481
[TBL] [Abstract][Full Text] [Related]
4. Modulation of dopaminergic neurotransmission in the 6-hydroxydopamine lesioned rotational model by peptidomimetic analogues of L-prolyl-L-leucyl-glycinamide.
Ott MC; Mishra RK; Johnson RL
Brain Res; 1996 Oct; 737(1-2):287-91. PubMed ID: 8930377
[TBL] [Abstract][Full Text] [Related]
5. MIF-I and postsynaptic receptor sites for dopamine.
Kostrzewa RM; Hardin JC; Snell RL; Kastin AJ; Coy DH; Bymaster F
Brain Res Bull; 1979; 4(5):657-62. PubMed ID: 39665
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of apomorphine-induced stereotypies by naloxone and L-prolyl-L-leucyl-glycinamide.
Quock RM; Lucas TS; Hartl TJ
Pharmacol Biochem Behav; 1983 Jul; 19(1):49-52. PubMed ID: 6137836
[TBL] [Abstract][Full Text] [Related]
7. Prolyl-leucyl-glycine amide (PLG) and thyrotropin-releasing hormone (TRH): DOPA potentiation and biogenic amine studies.
Plotnikoff NP
Prog Brain Res; 1975; 42():11-23. PubMed ID: 730
[No Abstract] [Full Text] [Related]
8. Striatal dopamine turnover and MIF-I.
Kostrzewa RM; Fukushima H; Harston CT; Perry KW; Fuller RW; Kastin AJ
Brain Res Bull; 1979; 4(6):799-802. PubMed ID: 43187
[TBL] [Abstract][Full Text] [Related]
9. Interaction of L-prolyl-L-leucyl glycinamide with dopamine D2 receptor: evidence for modulation of agonist affinity states in bovine striatal membranes.
Srivastava LK; Bajwa SB; Johnson RL; Mishra RK
J Neurochem; 1988 Mar; 50(3):960-8. PubMed ID: 2892892
[TBL] [Abstract][Full Text] [Related]
10. MIF-1 attenuates apomorphine stereotypies in adult rats after neonatal 6-hydroxydopamine.
Kostrzewa RM; White TG; Zadina JE; Kastin AJ
Eur J Pharmacol; 1989 Apr; 163(1):33-42. PubMed ID: 2568266
[TBL] [Abstract][Full Text] [Related]
11. Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings.
Chiu S; Paulose CS; Mishra RK
Peptides; 1981; 2(1):105-11. PubMed ID: 6113579
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological studies with a tripeptide, prolyl-leucyl glycine amide.
Plotnikoff NP; Kastin AJ
Arch Int Pharmacodyn Ther; 1974 Oct; 211(2):211-24. PubMed ID: 4156639
[No Abstract] [Full Text] [Related]
13. MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats.
Castellano JM; Batrynchuk J; Dolbeare K; Verma V; Mann A; Skoblenick KJ; Johnson RL; Mishra RK
Peptides; 2007 Oct; 28(10):2009-15. PubMed ID: 17766011
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG).
Rajakumar G; Naas F; Johnson RL; Chiu S; Yu KL; Mishra RK
Peptides; 1987; 8(5):855-61. PubMed ID: 2893360
[TBL] [Abstract][Full Text] [Related]
15. Are the pharmacological effects of L-prolyl-L-leucyl-glycinamide (PLG) mediated through specific receptor mechanisms?
Chiu S; Wong YW; Wan YP; Chiu P; Mishra RK
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):739-42. PubMed ID: 6141616
[TBL] [Abstract][Full Text] [Related]
16. Modulation of dopamine receptor agonist-induced rotational behavior in 6-OHDA-lesioned rats by a peptidomimetic analogue of Pro-Leu-Gly-NH2 (PLG).
Mishra RK; Marcotte ER; Chugh A; Barlas C; Whan D; Johnson RL
Peptides; 1997; 18(8):1209-15. PubMed ID: 9396063
[TBL] [Abstract][Full Text] [Related]
17. The action of prolyl-leucyl-glycinamide (PLG) on the nigrostriatal pathway of the rat.
Pereira JS; Andrade LA; Bertolucci PH; Lima JG; Ferraz HB
Arq Neuropsiquiatr; 1990 Jun; 48(2):156-60. PubMed ID: 1979732
[TBL] [Abstract][Full Text] [Related]
18. Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG).
Chiu P; Rajakumar G; Chiu S; Johnson RL; Mishra RK
Peptides; 1985; 6(2):179-83. PubMed ID: 2863809
[TBL] [Abstract][Full Text] [Related]
19. A comparison between a melanocyte-stimulating hormone inhibitory factor (MIF-I) and substances known to activate central dopamine receptors.
Cox B; Kastin AJ; Schnieden H
Eur J Pharmacol; 1976 Mar; 36(1):141-7. PubMed ID: 4332
[TBL] [Abstract][Full Text] [Related]
20. [The effect of prolyl-leucyl-glycine (MIF-1) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine levels of the striatum].
Sheng JG
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1989 Aug; 22(4):213-5, 253. PubMed ID: 2575971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
